Motalib Smahi

APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti‐Xa reagent used for correlation

Pierre Toulon, Motalib Smahi, Neila De Pooter · Journal of Thrombosis and Haemostasis · 2021 · 42 citations

Thrombosis, Anti‐xa Reagent, Significant Impact +7

<i>In vitro</i> sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies

Pierre Toulon, Yaelle Eloit, Motalib Smahi et al. · International Journal of Laboratory Hematology · 2016 · 40 citations · Full text

Monitoring unfractionated heparin therapy: Lack of standardization of anti‐Xa activity reagents

Motalib Smahi, Neila De Pooter, Martine J. Hollestelle et al. · Journal of Thrombosis and Haemostasis · 2020 · 35 citations

Thrombosis, Hepatology, Medicine +7

Age‐adjusted D‐dimer cut‐off levels to rule out venous thromboembolism in patients with non‐high pre‐test probability: Clinical performance and cost‐effectiveness analysis

Neila De Pooter, Marie Brionne‐François, Motalib Smahi et al. · Journal of Thrombosis and Haemostasis · 2021 · 22 citations

Thrombosis, D‐dimer Cut‐off Levels, Venous Thrombosis +12

Monitoring treatments with unfractionated heparin: CTAD must be used instead of citrate as the anticoagulant solution when using partial-draw collection tubes. Results of a multicenter evaluation

Pierre Toulon, L Abecassis, Motalib Smahi et al. · Thrombosis Research · 2010 · 13 citations

Thrombosis, Partial-draw Collection Tubes, Medicine +11